Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Gynecology

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 141 articles: HTML format

Single Articles

May 2026
1. QUAN J, Chen Q, Lan L, Zhang B, et al
   Type- and age-specific natural history of high-risk human papillomavirus infections in healthy women: A prospective cohort study in China.
   Int J Cancer. 2026;158:2736-2746.
   PubMed     Abstract available
   
   
   
2. ELFSTROM KM, Hortlund M, Ohman D, Dillner J, et al
   Cancer detection using human papillomavirus self-sampling targeting long-term non-attenders in an organized cervical screening program.
   Int J Cancer. 2026;158:2729-2735.
   PubMed     Abstract available
   
   
   
3. MONAHAN KJ, Fleming P, Ryan NAJ, Monje-Garcia L, et al
   Outcomes from the English National Lynch Syndrome transformation project.
   Int J Cancer. 2026;158:2369-2379.
   PubMed     Abstract available
   
   
   
4. LEI J, Falcaro M, Brentnall AR, O'Mahony JF, et al
   Indicators to identify cancer screening providers with suboptimal case detection: A scoping review.
   Int J Cancer. 2026;158:2339-2358.
   PubMed     Abstract available
   
   
   March 2026
5. CUI J, Mukherjee A, Patel PG, Junkins A, et al
   Sex and organ-specific risk and temporal trends of human papillomavirus-associated anogenital cancer among solid organ transplant recipients in the United States.
   Int J Cancer. 2026;158:1507-1516.
   PubMed     Abstract available
   
   
   
6. KARRBERG C, Gray P, Elfgren K, Milerad H, et al
   Nationwide audit of cervical cancer screening reveals unsatisfactory triage strategies and trends over time in incidence among cytology negative women.
   Int J Cancer. 2026 Mar 9. doi: 10.1002/ijc.70415.
   PubMed     Abstract available
   
   
   
7. KALJOUW S, Jansen EEL, Olthof EMG, Hontelez JAC, et al
   Under which realistic circumstances is hrHPV self-sampling increasing cervical screening effectiveness in a partly vaccinated population? A modelling study.
   Int J Cancer. 2026;158:1361-1369.
   PubMed     Abstract available
   
   
   February 2026
8. SAKAGUCHI-MUKAIDA H, Hiramatsu K, Masuda T, Kakuda M, et al
   Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer.
   Int J Cancer. 2026 Feb 26. doi: 10.1002/ijc.70401.
   PubMed     Abstract available
   
   
   
9. LAI SW, Liao KF
   Comment on "Association of aspirin and ibuprofen use with endometrial cancer risk in the PLCO dataset".
   Int J Cancer. 2026 Feb 19. doi: 10.1002/ijc.70392.
   PubMed    
   
   
   
10. VAHTERISTO M, Heinavaara S, Dillner J, Kalliala I, et al
    Long-term human papillomavirus genotype-specific risk of cervical high-grade intraepithelial lesion and cancer-By age group and triage cytology.
    Int J Cancer. 2026;158:931-941.
    PubMed     Abstract available
    
    
    
11. STANKIEWICZ KARITA HC, Magaret AS, Doody DR, Schouten JT, et al
    Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial.
    Int J Cancer. 2026 Feb 13. doi: 10.1002/ijc.70366.
    PubMed     Abstract available
    
    
    
12. OH M, An KY, Lee DH, Kokts-Porietis RL, et al
    Long-term association of physical activity with survival by primary cancer treatment in endometrial cancer: The Alberta Endometrial Cancer Cohort Study.
    Int J Cancer. 2026 Feb 10. doi: 10.1002/ijc.70369.
    PubMed     Abstract available
    
    
    
13. DE CARVALHO TM, Berkhof J, Bogaards JA
    Cost-effectiveness of risk-stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage.
    Int J Cancer. 2026 Feb 9. doi: 10.1002/ijc.70377.
    PubMed     Abstract available
    
    
    
14. SNELLMAN J, Pankakoski M, Heinavaara S, Partanen VM, et al
    Increased cervical cancer incidence in the target age of screening-Variation by mode of detection.
    Int J Cancer. 2026 Feb 7. doi: 10.1002/ijc.70371.
    PubMed     Abstract available
    
    
    
15. RASMUSSEN RMW, Munk C, Kjaer SK
    Is the beneficial effect of multi-cohort HPV vaccination on cervical cancer and precancerous lesions seen across all educational levels?
    Int J Cancer. 2026 Feb 6. doi: 10.1002/ijc.70360.
    PubMed     Abstract available
    
    
    
16. NOUWENS AJ, Schaafsma M, van Trommel NE, Kasius JC, et al
    Detection of recurrent endometrial cancer via DNA methylation analysis of cervicovaginal self-samples and urine.
    Int J Cancer. 2026 Feb 6. doi: 10.1002/ijc.70358.
    PubMed     Abstract available
    
    
    
17. FRAYLE H, Gori S, Pagan A, Solda M, et al
    Predictive biomarkers for regression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2: A prospective multicenter study in Italy.
    Int J Cancer. 2026;158:587-596.
    PubMed     Abstract available
    
    
    January 2026
18. REDL E, Herzog C, Vavourakis C, Barrett J, et al
    The cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer.
    Int J Cancer. 2026 Jan 29. doi: 10.1002/ijc.70354.
    PubMed     Abstract available
    
    
    
19. KROON KR, Bogaards JA, Berkhof J
    Cost-effectiveness analysis of human papillomavirus (HPV) genotyping strategies for management of HPV-positive women in cervical cancer screening.
    Int J Cancer. 2026 Jan 28. doi: 10.1002/ijc.70344.
    PubMed     Abstract available
    
    
    
20. JIANG M, Yamaguchi K, Hamada K, Hosoe Y, et al
    HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma.
    Int J Cancer. 2026 Jan 27. doi: 10.1002/ijc.70341.
    PubMed     Abstract available
    
    
    
21. GIES S, Pohlers M, Tanzer T, Ampofo E, et al
    Th17 cells favor migration and invasiveness of cervical cancer cells under hypoxia in an IGF2BP2-dependent manner.
    Int J Cancer. 2026 Jan 24. doi: 10.1002/ijc.70340.
    PubMed     Abstract available
    
    
    
22. NOMM O, Innos K, Jasilionis D, Krumins J, et al
    Educational inequalities in cervical cancer mortality in the Baltic countries and Finland in the context of organized screening: A register-based study 2000-2015.
    Int J Cancer. 2026 Jan 24. doi: 10.1002/ijc.70339.
    PubMed     Abstract available
    
    
    
23. LEHTINEN M, Lipsitch M, Pimenoff VN, Sundstrom K, et al
    Predicting optimal impact interventions in the post-HPV vaccination world.
    Int J Cancer. 2026 Jan 19. doi: 10.1002/ijc.70297.
    PubMed     Abstract available
    
    
    
24. NAM SY, Jo J
    The effect of body mass index change on breast and uterine cancer risk in middle- and older-aged adults.
    Int J Cancer. 2026 Jan 2. doi: 10.1002/ijc.70325.
    PubMed     Abstract available
    
    
    
25. SABBAGHIAN A, Lin H, Lim YP
    WBP2 and its network of transcription coregulators in an expanding repertoire of human cancers.
    Int J Cancer. 2026;158:218-231.
    PubMed     Abstract available
    
    
    December 2025
26. TSEGAYE AT, Mashele SA, Shing JZ, Mwansa-Kambafwile J, et al
    Race-specific temporal trends of HPV-related cancers in South Africa: An analysis of the South African National Cancer Registry, 2011-2022.
    Int J Cancer. 2025 Dec 31. doi: 10.1002/ijc.70323.
    PubMed     Abstract available
    
    
    
27. HARRELL AN, O'Brien KM, Shaw ND, Sandler DP, et al
    Pubertal timing and incident uterine cancer in the Sister Study cohort.
    Int J Cancer. 2025 Dec 24. doi: 10.1002/ijc.70310.
    PubMed     Abstract available
    
    
    
28. WIDJAJA AO, Micallef P, Lycke M, Osterlund T, et al
    Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.
    Int J Cancer. 2025 Dec 9. doi: 10.1002/ijc.70277.
    PubMed     Abstract available
    
    
    
29. HU Y, Liu Y, Guo W, Hong Z, et al
    Efficacy and safety of 5-aminolevulinic acid-based photodynamic therapy for cervical low-grade squamous intraepithelial lesions with HPV infections.
    Int J Cancer. 2025 Dec 8. doi: 10.1002/ijc.70273.
    PubMed     Abstract available
    
    
    November 2025
30. AZAM Z, Zhang X, Wahab R, Hasan MM, et al
    Doppel as an early-stage biomarker promoting EMT and dissemination in ovarian cancers.
    Int J Cancer. 2025 Nov 29. doi: 10.1002/ijc.70268.
    PubMed     Abstract available
    
    
    
31. 
    Correction to "Prospective evaluation of 92 protein biomarkers for early detection of endometrial cancer".
    Int J Cancer. 2025 Nov 28. doi: 10.1002/ijc.70261.
    PubMed    
    
    
    
32. PENG H, Li J, Zhou Q, Zhou H, et al
    Enhanced diagnostic accuracy of high-grade cervical intraepithelial neoplasia in postmenopausal women through PAX1/JAM3 methylation analysis.
    Int J Cancer. 2025 Nov 14. doi: 10.1002/ijc.70245.
    PubMed     Abstract available
    
    
    
33. DENG C, Hu YH, Sirirungreung A, Chock EY, et al
    Exposure to nitrosatable drugs during pregnancy and childhood cancer: A cohort study in Taiwan.
    Int J Cancer. 2025 Nov 7. doi: 10.1002/ijc.70240.
    PubMed     Abstract available
    
    
    
34. ORTEGA LLOBET M, Gray P, Baussano I, Elfstrom KM, et al
    Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated women.
    Int J Cancer. 2025 Nov 7. doi: 10.1002/ijc.70229.
    PubMed     Abstract available
    
    
    
35. NEWTON R, Tenet V, Mugisha J, Kimono B, et al
    Human papillomavirus infection and vaccination among young females in rural Uganda.
    Int J Cancer. 2025 Nov 6. doi: 10.1002/ijc.70227.
    PubMed     Abstract available
    
    
    
36. SA P, Monteiro P, Henrique R, Lunet N, et al
    The cervical cancer screening program in the North of Portugal: Outcomes after nearly two decades of coexistence with the human papillomavirus vaccine.
    Int J Cancer. 2025 Nov 3. doi: 10.1002/ijc.70196.
    PubMed     Abstract available
    
    
    
37. PALMER TJ, Kavanagh K, Cuschieri K, Cameron RL, et al
    Sustained impact of bivalent HPV immunisation on CIN incidence over two rounds of cervical screening.
    Int J Cancer. 2025 Nov 3. doi: 10.1002/ijc.70183.
    PubMed     Abstract available
    
    
    
38. HABIBURRAHMAN M, Masrour N, Patel N, Piskorz AM, et al
    Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients.
    Int J Cancer. 2025 Nov 1. doi: 10.1002/ijc.70217.
    PubMed     Abstract available
    
    
    October 2025
39. CHINULA L, Chagomerana MB, Mkochi T, Msowoya L, et al
    Single visit screen-triage-treat strategy using GeneXpert-based HPV testing of self-collected cervicovaginal samples and thermal ablation treatment for cervical cancer prevention among women in Lilongwe, Malawi.
    Int J Cancer. 2025 Oct 16. doi: 10.1002/ijc.70177.
    PubMed     Abstract available
    
    
    
40. HERNANDEZ-BERNAL F, Bernal KS, Bequet-Romero M, Martin-Bauta Y, et al
    HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: Phase II CENTAURO-4 trial results.
    Int J Cancer. 2025 Oct 16. doi: 10.1002/ijc.70199.
    PubMed     Abstract available
    
    
    
41. YU X, Nzoutchoum OL, Gao D, Hsu CD, et al
    Cervical cancer screening and prevalence among older US Medicare beneficiaries with and without HIV.
    Int J Cancer. 2025 Oct 13. doi: 10.1002/ijc.70193.
    PubMed     Abstract available
    
    
    
42. KIVIHARJU M, Riska A, Kalliala I, Jakobsson M, et al
    Randomised trial on treatment of vaginal high-grade squamous intraepithelial lesion: Self-administered vaginal imiquimod and laser vaporisation.
    Int J Cancer. 2025;157:1458-1464.
    PubMed     Abstract available
    
    
    September 2025
43. WANG L, Zang Y, Dejenie R, Bing J, et al
    The role of cytokines in ovarian cancer drug resistance.
    Int J Cancer. 2025 Sep 19. doi: 10.1002/ijc.70099.
    PubMed     Abstract available
    
    
    
44. KOESTLER AJ, Nelson CW, Yeager M, Chen Z, et al
    Whole-genome sequencing of 1,083 HPV45 cases and controls identifies genetic variants associated with glandular cervical lesions.
    Int J Cancer. 2025;157:1130-1141.
    PubMed     Abstract available
    
    
    
45. ULLAH A, Chen Y, Shen Y, Shen B, et al
    Chemotherapy as a double-edged sword: Modulation of tumor-associated cytokine and chemokine responses in ovarian cancer.
    Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70132.
    PubMed     Abstract available
    
    
    
46. TOTA JE, Shing JZ, Roberts JN, Anderson EM, et al
    Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era.
    Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70119.
    PubMed     Abstract available
    
    
    
47. ANDERSEN K, Bonde J, Waldstrom M, Jakobsen MV, et al
    Evaluation of targeted next-generation sequencing for detection of HPV genotypes and sublineages in cervical liquid-based cytology SurePath samples from the Danish screening program.
    Int J Cancer. 2025 Sep 11. doi: 10.1002/ijc.70148.
    PubMed     Abstract available
    
    
    
48. LIU H, Zou Z, Zhang L
    Reply to 'Comments on "HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis"'.
    Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70129.
    PubMed    
    
    
    
49. LIU Z, Tong X
    Comments on "HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis".
    Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70130.
    PubMed    
    
    
    
50. CASTANEDA KM, Vermeulen KM, van der Aa M, Schuuring E, et al
    Trends in cervical cancer incidence in the Netherlands: A join-point and age-period-cohort analysis (1989-2023).
    Int J Cancer. 2025 Sep 8. doi: 10.1002/ijc.70134.
    PubMed     Abstract available
    
    
    
51. KASPER E, Boulouard F, Basset N, Golmard L, et al
    Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.
    Int J Cancer. 2025;157:897-907.
    PubMed     Abstract available
    
    
    August 2025
52. DAUGS K, Brandes D, Yasin L, Anwar A, et al
    Germline variants observed in pediatric cancer patients related to hereditary breast and ovarian cancer in adults.
    Int J Cancer. 2025 Aug 26. doi: 10.1002/ijc.70097.
    PubMed     Abstract available
    
    
    
53. ZHAO Y, Wang Y, Zhang Y, Han Q, et al
    Association of aspirin and ibuprofen use with endometrial cancer risk in the PLCO dataset.
    Int J Cancer. 2025 Aug 21. doi: 10.1002/ijc.70101.
    PubMed     Abstract available
    
    
    
54. LI H, Feng Y, Wang Z, Li X, et al
    Advances in the management of ovarian cancer liver metastasis.
    Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70065.
    PubMed     Abstract available
    
    
    
55. KAUPPINEN AK, Olkinuora AP, Mecklin JP, Peltomaki PT, et al
    Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome.
    Int J Cancer. 2025 Aug 7. doi: 10.1002/ijc.70074.
    PubMed     Abstract available
    
    
    July 2025
56. BOWDEN SJ, Bodinier B, Paraskevaidi M, Kalliala I, et al
    DNA methylation signatures of cervical pre-invasive and invasive disease: An epigenome-wide association study.
    Int J Cancer. 2025;157:305-316.
    PubMed     Abstract available
    
    
    
57. BJORGE T, Stoer NC, Hverven SK, Nygard M, et al
    Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study.
    Int J Cancer. 2025;157:251-259.
    PubMed     Abstract available
    
    
    
58. BEIERLEIN M, Haberle L, Nabieva N, Maass N, et al
    Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.
    Int J Cancer. 2025 Jul 11. doi: 10.1002/ijc.70037.
    PubMed     Abstract available
    
    
    
59. CHANDRAN A, Mackie A, Sasieni P, Arbyn M, et al
    Technical, legal and ethical framework of cancer audit in cervical screening - Summary of best practices for organised programmes delineated through an expert group consultation.
    Int J Cancer. 2025;157:32-40.
    PubMed     Abstract available
    
    
    June 2025
60. WEI SQ, Leduc V, Potter B, Paradis G, et al
    Preeclampsia and risk of breast cancer: A longitudinal cohort study of tumor histology.
    Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70025.
    PubMed     Abstract available
    
    
    
61. ZHENG Y, Han J, Qu Y, Wang J, et al
    DNA methylation biomarkers for cervical cancer risk prediction in HIV-positive Nigerian women.
    Int J Cancer. 2025 Jun 9. doi: 10.1002/ijc.35502.
    PubMed     Abstract available
    
    
    
62. JENKINS M, Saidu R, Boa R, Mbatani N, et al
    Performance of thermoablation among women treated for high-risk human papillomavirus in a screen-and-treat program in South Africa.
    Int J Cancer. 2025 Jun 6. doi: 10.1002/ijc.35519.
    PubMed     Abstract available
    
    
    
63. HEMMINGSEN CH, Kjaer SK, Hjorth S, Norby U, et al
    Maternal hormonal contraceptive use and childhood central nervous system tumor risk in a large Scandinavian cohort.
    Int J Cancer. 2025 Jun 5. doi: 10.1002/ijc.35509.
    PubMed     Abstract available
    
    
    May 2025
64. KJAER SK, Frederiksen K, Rasmussen CL, Thomsen LT, et al
    Prognostic impact of p16 and high-risk HPV DNA in ~1300 patients with vulvar cancer.
    Int J Cancer. 2025 May 30. doi: 10.1002/ijc.35501.
    PubMed     Abstract available
    
    
    
65. GAMA Q, Wang L, Wu P, Liu S, et al
    Effects of levonorgestrel-releasing intrauterine system on recurrence and fertility outcomes during assisted reproduction after complete remission of early endometrioid endometrial cancer and precancerous lesions: A retrospective cohort study.
    Int J Cancer. 2025 May 14. doi: 10.1002/ijc.35465.
    PubMed     Abstract available
    
    
    
66. DAMGAARD R, Jenkins D, Stoler MH, van de Sandt M, et al
    p16(INK4a) and HPV E4 immunohistochemistry for the prediction of regression of cervical intraepithelial neoplasia grade 2-A historical cohort study.
    Int J Cancer. 2025 May 5. doi: 10.1002/ijc.35469.
    PubMed     Abstract available
    
    
    April 2025
67. KALJOUW S, Jansen EEL, Schevenhoven VJC, de Kok IMCM, et al
    Should the age range of the Dutch hrHPV-based cervical cancer screening program be broadened? A modelling study using cohort effects.
    Int J Cancer. 2025 Apr 28. doi: 10.1002/ijc.35435.
    PubMed     Abstract available
    
    
    
68. WEI Y, Gu L, Zhang Y, Yang Q, et al
    Efficacy of ALA-PDT in treating cervical low-grade squamous intraepithelial lesions with high-risk HPV patients: A multicentre randomized controlled trial.
    Int J Cancer. 2025 Apr 23. doi: 10.1002/ijc.35450.
    PubMed     Abstract available
    
    
    
69. WITJES VM, de Hullu JA, Hermkens DMA, Smolders YHCM, et al
    Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.
    Int J Cancer. 2025 Apr 16. doi: 10.1002/ijc.35440.
    PubMed     Abstract available
    
    
    
70. GE X, Feng Y, Tan S, Mao W, et al
    Gestational colorectal cancer: Mechanisms, treatments, and prognosis.
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35425.
    PubMed     Abstract available
    
    
    
71. COOLEY V, Fortner RT, Mukama T, Naudin S, et al
    Prospective evaluation of 92 protein biomarkers for early detection of endometrial cancer.
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35428.
    PubMed     Abstract available
    
    
    March 2025
72. ESLAHI M, Pizzato M, Heikkinen S, Martinsen JI, et al
    Socioeconomic position and risk of cervical cancer in the Nordic countries: Results from the Nordic Occupational Cancer Study.
    Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35349.
    PubMed     Abstract available
    
    
    
73. LI Z, Liu P, Yin A, Zhang B, et al
    Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer.
    Int J Cancer. 2025 Mar 3. doi: 10.1002/ijc.35369.
    PubMed     Abstract available
    
    
    
74. WEI W, Zhang Y, Li Y, Huang J, et al
    Hypoxia-mediated high expression of TRIM15 promotes malignant progression of high-grade serous ovarian cancer through activation of AKT signaling pathway by K63 ubiquitination.
    Int J Cancer. 2025 Mar 3. doi: 10.1002/ijc.35387.
    PubMed     Abstract available
    
    
    
75. CHEN Q, Yao X, Quan J, Jia X, et al
    The variations in the natural history of high-risk human papillomavirus infections in Chinese healthy women aged 27-45 years compared with 18-26 years: A prospective cohort study.
    Int J Cancer. 2025;156:1043-1054.
    PubMed     Abstract available
    
    
    February 2025
76. HAUG AJ, Stoer N, Langseth H, Siafarikas F, et al
    Non-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study.
    Int J Cancer. 2025 Feb 24. doi: 10.1002/ijc.35363.
    PubMed     Abstract available
    
    
    
77. NICHOLS HB, Anderson C, Baggett CD, Cannizzaro NT, et al
    Pregnancy and pregnancy outcomes after adolescent and young adult cancer in the AYA horizon study.
    Int J Cancer. 2025 Feb 24. doi: 10.1002/ijc.35383.
    PubMed     Abstract available
    
    
    
78. PEREMIQUEL-TRILLAS P, Martinez JM, Paytubi S, Frias-Gomez J, et al
    Acceptability and somatic mutations in cervicovaginal self-sampling for early endometrial cancer detection in women with Lynch syndrome.
    Int J Cancer. 2025 Feb 14. doi: 10.1002/ijc.35368.
    PubMed     Abstract available
    
    
    
79. KEBEDE HB, Mekuria S, Asegid N, Forslund O, et al
    High-risk human papillomavirus genotypes in previously unscreened reproductive-age women in Ethiopia: A community-based cohort study.
    Int J Cancer. 2025 Feb 14. doi: 10.1002/ijc.35335.
    PubMed     Abstract available
    
    
    
80. RUNELLO F, Jary A, Duin S, Kim Y, et al
    DNA methylation and copy number alterations in the progression of HPV-associated high-grade vulvar intraepithelial lesion.
    Int J Cancer. 2025 Feb 12. doi: 10.1002/ijc.35366.
    PubMed     Abstract available
    
    
    
81. HARPER DM, Paczos T, Ridder R, Huh WK, et al
    p16/ki-67 dual stain triage of individuals positive for HPV to detect cervical precancerous lesions.
    Int J Cancer. 2025 Feb 4. doi: 10.1002/ijc.35353.
    PubMed     Abstract available
    
    
    January 2025
82. LOFLING LL, Stoer NC, Sloan EK, Nafisi S, et al
    Beta-blockers and epithelial ovarian cancer survival: A Norwegian population-based cohort study.
    Int J Cancer. 2025 Jan 26. doi: 10.1002/ijc.35348.
    PubMed     Abstract available
    
    
    
83. DU L, Sun H, Tang L, Hao S, et al
    Cervical cancer incidence rates considering migration status in mainland China using Bayesian model-Estimation based on 2016 cancer registry data.
    Int J Cancer. 2025 Jan 23. doi: 10.1002/ijc.35346.
    PubMed     Abstract available
    
    
    
84. ARROYO MUHR LS, Wang J, Hassan SS, Yilmaz E, et al
    Nationwide registry-based trial of risk-stratified cervical screening.
    Int J Cancer. 2025;156:379-388.
    PubMed     Abstract available
    
    
    
85. LUND E, Busund LR, Holden L
    Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.
    Int J Cancer. 2025 Jan 3. doi: 10.1002/ijc.35312.
    PubMed     Abstract available
    
    
    December 2024
86. VERROU E, Koutoukoglou P, Kontana E, Gogolopoulos S, et al
    Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience.
    Int J Cancer. 2024 Dec 17. doi: 10.1002/ijc.35299.
    PubMed     Abstract available
    
    
    
87. VERHOEF L, Bleeker MCG, Polman N, Kroon KR, et al
    Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and/or HPV genotyping in HPV positive women with low-grade cytology from a population-based Dutch primary HPV screening trial.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35289.
    PubMed     Abstract available
    
    
    
88. HUNG FH, Peng HP, Hung CF, Hsieh LL, et al
    Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan.
    Int J Cancer. 2024;155:2201-2210.
    PubMed     Abstract available
    
    
    
89. KEN-AMOAH S, Redl E, Domson BKS, Barrett JE, et al
    Performance of the WID-qEC test to detect uterine cancers in black women with abnormal uterine bleeding: A prospective observational cohort study in Ghana.
    Int J Cancer. 2024 Dec 10. doi: 10.1002/ijc.35260.
    PubMed     Abstract available
    
    
    
90. TUNG HJ, Wang YC, Lin CY, Liao MJ, et al
    Human papillomavirus prevalence, genotype distribution, and prognostic factors of vaginal cancer.
    Int J Cancer. 2024;155:1996-2008.
    PubMed     Abstract available
    
    
    November 2024
91. PEDERSEN BT, Sonne SB, Pedersen H, Andreasen EK, et al
    Participation and relative cost of attendance by direct-mail compared to opt-in invitation strategy for HPV self-sampling targeting cervical screening non-attenders: A large-scale, randomized, pragmatic study.
    Int J Cancer. 2024 Nov 23. doi: 10.1002/ijc.35263.
    PubMed     Abstract available
    
    
    
92. LIU H, Zou M, Shen M, Kamarulzaman A, et al
    HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis.
    Int J Cancer. 2024 Nov 17. doi: 10.1002/ijc.35242.
    PubMed     Abstract available
    
    
    
93. JENSEN A, Guleria S, Albieri V, Nohr B, et al
    Fertility treatment and risk of ovarian cancer in a large nationwide cohort of infertile Danish women.
    Int J Cancer. 2024 Nov 14. doi: 10.1002/ijc.35251.
    PubMed     Abstract available
    
    
    
94. BONAVENTURE A, Simpson J, Kane E, Roman E, et al
    Maternal illnesses during pregnancy and the risk of childhood cancer: A medical-record based analysis (UKCCS).
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35166.
    PubMed     Abstract available
    
    
    
95. WATLING CZ, Kelly RK, Watts EL, Graubard BI, et al
    Total testosterone, sex hormone-binding globulin, and free testosterone concentrations and risk of primary liver cancer: A prospective analysis of 200,000 men and 180,000 postmenopausal women.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35244.
    PubMed     Abstract available
    
    
    
96. SCHAAFSMA M, Schuurman TN, Kootstra P, Issa D, et al
    Nationwide cohort study on the risk of high-grade cervical dysplasia and carcinoma after conservative treatment or hysterectomy for adenocarcinoma in situ.
    Int J Cancer. 2024 Nov 4. doi: 10.1002/ijc.35237.
    PubMed     Abstract available
    
    
    
97. SCHEI-ANDERSEN AJ, Hendricks LAJ, van der Post RS, Mensenkamp AR, et al
    Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single-center study.
    Int J Cancer. 2024;155:1567-1576.
    PubMed     Abstract available
    
    
    
98. LOUVANTO K, Verhoef L, Pimenoff V, Eriksson T, et al
    Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions.
    Int J Cancer. 2024;155:1549-1557.
    PubMed     Abstract available
    
    
    October 2024
99. DESCAMPS P, Bosch Jose FX, Monsonego J, Neisingh O, et al
    Cervical cancer screening: Sharing best practices and addressing common challenges in cervical cancer screening programs.
    Int J Cancer. 2024 Oct 26. doi: 10.1002/ijc.35220.
    PubMed    
    
    
    
100. LEHTINEN M, Elfstrom M, Vanska S, Dillner J, et al
     Elimination of cervical cancer by refined vaccination and screening.
     Int J Cancer. 2024 Oct 25. doi: 10.1002/ijc.35228.
     PubMed    
     
     
     
101. KOKEMULLER L, Ramachandran D, Schurmann P, Geffers R, et al
     Germline variants of homology-directed repair or mismatch repair genes in cervical cancer.
     Int J Cancer. 2024 Oct 23. doi: 10.1002/ijc.35221.
     PubMed     Abstract available
     
     
     
102. BIGNOTTI E, Simeon V, Ardighieri L, Kuhn E, et al
     TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
     Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35203.
     PubMed     Abstract available
     
     
     
103. MISHRA GA, Pimple SA, Anand KV, Kulkarni VY, et al
     Acceptability and validity of HPV self-sampling for cervical cancer screening among women living in different ecological settings in India.
     Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35222.
     PubMed     Abstract available
     
     
     
104. ZHENG Y, Vdovichenko N, Schurmann P, Ramachandran D, et al
     Comparative sequencing study of mismatch repair and homology-directed repair genes in endometrial cancer and breast cancer patients from Kazakhstan.
     Int J Cancer. 2024 Oct 14. doi: 10.1002/ijc.35215.
     PubMed     Abstract available
     
     
     
105. CUI M, Song L, Mao R, Lyu Y, et al
     Exposure to polycyclic aromatic hydrocarbons promotes the progression of low-grade cervical intraepithelial neoplasia: A population-based cohort study in China.
     Int J Cancer. 2024;155:1162-1171.
     PubMed     Abstract available
     
     
     September 2024
106. CHEN J, Shi J, Cao Y, Li C, et al
     A new treatment approach of toripalimab in combination with concurrent platinum-based chemoradiotherapy for locally advanced cervical cancer: A phase II clinical trial.
     Int J Cancer. 2024 Sep 28. doi: 10.1002/ijc.35206.
     PubMed     Abstract available
     
     
     
107. JONSSON S, Jonsson H, Lundin E, Haggstrom C, et al
     Pelvic inflammatory disease and risk of borderline ovarian tumors: A national population-based case-control study in Sweden.
     Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35180.
     PubMed     Abstract available
     
     
     
108. DEBEAUDRAP P, Kabore FN, Setha L, Tegbe J, et al
     Performance of visual inspection, partial genotyping, and their combination for the triage of women living with HIV who are screen positive for human papillomavirus: Results from the AIMA-CC ANRS 12375 multicentric screening study.
     Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35190.
     PubMed     Abstract available
     
     
     
109. OSTRBENK VALENCAK A, Kroon KR, Fabjan D, Mlakar J, et al
     Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.
     Int J Cancer. 2024 Sep 24. doi: 10.1002/ijc.35200.
     PubMed     Abstract available
     
     
     
110. NA R, Jordan SJ, DeFazio A, Williams M, et al
     Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival-A prospective cohort study in Australia.
     Int J Cancer. 2024 Sep 2. doi: 10.1002/ijc.35154.
     PubMed     Abstract available
     
     
     
111. FUJITA M, Nagashima K, Shimazu M, Suzuki M, et al
     Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan: The ACCESS randomized controlled trial.
     Int J Cancer. 2024;155:905-915.
     PubMed     Abstract available
     
     
     August 2024
112. VLEDDER A, Paijens ST, Loiero D, Maagdenberg A, et al
     B cells critical for outcome in high grade serous ovarian carcinoma.
     Int J Cancer. 2024 Aug 22. doi: 10.1002/ijc.35149.
     PubMed     Abstract available
     
     
     
113. SCHAAFSMA M, van den Helder R, Mom CH, Steenbergen RDM, et al
     Recurrent cervical cancer detection using DNA methylation markers in self-collected samples from home.
     Int J Cancer. 2024 Aug 22. doi: 10.1002/ijc.35143.
     PubMed     Abstract available
     
     
     July 2024
114. 
     Expression of Concern: miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
     Int J Cancer. 2024 Jul 31. doi: 10.1002/ijc.35121.
     PubMed    
     
     
     
115. KADERLY RASMUSSEN EL, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al
     Biopsy-verified vulvar lichen sclerosus and the risk of non-vulvar cancer: A nationwide cohort study.
     Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35101.
     PubMed     Abstract available
     
     
     
116. LYNGE E, Bennekou Schroll J, Andersen B, Balasubramaniam K, et al
     Cervical cancer incidence in Denmark: Disentangling determinants of time trend.
     Int J Cancer. 2024 Jul 14. doi: 10.1002/ijc.35081.
     PubMed     Abstract available
     
     
     
117. MORO F, Ciancia M, Zace D, Vagni M, et al
     Role of artificial intelligence applied to ultrasound in gynecology oncology: A systematic review.
     Int J Cancer. 2024 Jul 11. doi: 10.1002/ijc.35092.
     PubMed     Abstract available
     
     
     
118. GILHAM C, Nedjai B, Scibior-Bentkowska D, Reuter C, et al
     Long-term prediction by DNA methylation of high-grade cervical intraepithelial neoplasia: Results of the ARTISTIC cohort.
     Int J Cancer. 2024;155:81-92.
     PubMed     Abstract available
     
     
     June 2024
119. 
     Correction to "Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer".
     Int J Cancer. 2024 Jun 21. doi: 10.1002/ijc.35059.
     PubMed    
     
     
     
120. ALHARBI M, Lai A, Godbole N, Guanzon D, et al
     Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering.
     Int J Cancer. 2024 Jun 7. doi: 10.1002/ijc.35055.
     PubMed     Abstract available
     
     
     May 2024
121. LOBIN C, Orang'o EO, Were E, Muthoka K, et al
     Cost-effectiveness analysis of alternative screening strategies for the detection of cervical cancer among women in rural areas of Western Kenya.
     Int J Cancer. 2024 May 27. doi: 10.1002/ijc.35036.
     PubMed     Abstract available
     
     
     
122. CHAO X, Kai Z, Wu H, Wang J, et al
     Fragmentomics features of ovarian cancer.
     Int J Cancer. 2024 May 20. doi: 10.1002/ijc.34981.
     PubMed     Abstract available
     
     
     
123. HANSEN BT, Nygard M, Castle PE, Burger EA, et al
     Sociodemographic characteristics associated with cervical cancer screening participation by send-to-all and opt-in HPV self-sampling: Who benefits? Results from a randomized controlled trial among long-term non-attending women in Norway.
     Int J Cancer. 2024 May 15. doi: 10.1002/ijc.34989.
     PubMed     Abstract available
     
     
     
124. ILLAH O, Scott M, Redl E, Barrett JE, et al
     High performance of the DNA methylation-based WID-qEC test for detecting uterine cancers independent of sampling modalities.
     Int J Cancer. 2024 May 13. doi: 10.1002/ijc.35000.
     PubMed     Abstract available
     
     
     
125. ROSTAMI S, Rounge TB, Pestarino L, Lyle R, et al
     Differential levels of circulating RNAs prior to endometrial cancer diagnosis.
     Int J Cancer. 2024 May 11. doi: 10.1002/ijc.34951.
     PubMed     Abstract available
     
     
     
126. HUANG C, Bu H, Wang Y, Chu R, et al
     Association between coffee and tea consumption and ovarian cancer incidence: A prospective analysis in the PLCO dataset.
     Int J Cancer. 2024 May 11. doi: 10.1002/ijc.34982.
     PubMed     Abstract available
     
     
     
127. TAGUCHI A, Kato K, Furusawa A, Hara K, et al
     Heterogeneous treatment effect of dose-dense paclitaxel plus carboplatin therapy for advanced ovarian cancer.
     Int J Cancer. 2024 May 7. doi: 10.1002/ijc.34996.
     PubMed     Abstract available
     
     
     
128. FROMHAGE G, Obermayr E, Bednarz-Knoll N, Van Gorp T, et al
     Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
     Int J Cancer. 2024 May 6. doi: 10.1002/ijc.34976.
     PubMed     Abstract available
     
     
     
129. KITAHARA CM, Surcel HM, Falk R, Pfeiffer RM, et al
     Early-pregnancy sex steroid and thyroid function hormones, thyroid autoimmunity, and maternal papillary thyroid cancer incidence in the Finnish Maternity Cohort.
     Int J Cancer. 2024 May 2. doi: 10.1002/ijc.34974.
     PubMed     Abstract available
     
     
     April 2024
130. OBERMAYR E, Mohr T, Schuster E, Braicu EI, et al
     Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
     Int J Cancer. 2024 Apr 27. doi: 10.1002/ijc.34978.
     PubMed     Abstract available
     
     
     
131. BUDUKH A, Dora T, Sancheti S, Singh V, et al
     Outcome of early detection approach in control of breast, cervical, and oral cancer: Experience from a rural cancer center in India.
     Int J Cancer. 2024 Apr 20. doi: 10.1002/ijc.34966.
     PubMed     Abstract available
     
     
     
132. DOWNHAM L, Rol ML, Forestier M, Romero P, et al
     Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.
     Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34953.
     PubMed     Abstract available
     
     
     
133. SINGINI MG, Muchengeti M, Sitas F, Chen WC, et al
     Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
     Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34919.
     PubMed     Abstract available
     
     
     March 2024
134. DUUS AH, Hannibal CG, Baandrup L, Zheng G, et al
     Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer: The Extreme study.
     Int J Cancer. 2024 Mar 26. doi: 10.1002/ijc.34936.
     PubMed     Abstract available
     
     
     
135. BAANDRUP L, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al
     Biopsy-verified vulvar lichen sclerosus: Incidence trends 1997-2022 and increased risk of vulvar squamous precancer and squamous cell carcinoma.
     Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34927.
     PubMed     Abstract available
     
     
     
136. LI N, Yi H, Sun W, Sundquist J, et al
     Revealing genes associated with cervical cancer in distinct immune cells: A comprehensive Mendelian randomization analysis.
     Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34911.
     PubMed     Abstract available
     
     
     
137. HOLY P, Hlavac V, Seborova K, Susova S, et al
     Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
     Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34908.
     PubMed     Abstract available
     
     
     
138. STERPETTI AV, Gabriele R, Iannone I, Sapienza P, et al
     Reduced adherence to cervical cancer screening. The importance of information and education for women with low education and low-income.
     Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34907.
     PubMed    
     
     
     
139. OLTHOF EMG, Aitken CA, Siebers AG, van Kemenade FJ, et al
     The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.
     Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34902.
     PubMed     Abstract available
     
     
     February 2024
140. LINDQUIST S, Frederiksen K, Petersen LK, Kjaer SK, et al
     The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
     Int J Cancer. 2024 Feb 28. doi: 10.1002/ijc.34896.
     PubMed     Abstract available
     
     
     
141. WEN TM, Xu XQ, Zhao XL, Pan CH, et al
     Efficacy and immunogenicity of AS04-HPV-16/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide.
     Int J Cancer. 2024 Feb 17. doi: 10.1002/ijc.34882.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum